Abbreviated New Drug Application (ANDA): Generics > Generic Drug Review Dashboard Report
The U.S. Food and Drug Administration’s Office of Generic Drugs (OGD) has posted its third quarterly update of the Generic Drug Review Dashboard Report. This report includes current submission status for the total original abbreviated new drug application (ANDA) workload as well as review activities and communications tracking. OGD is providing this update to improve transparency as we continue implementation of the Generic Drug User Fee Amendments of 2012 (GDUFA), which is part of OGD’s comprehensive and ongoing efforts to make quality, affordable generic medicines available to the American public.
BMC Medical Genetics | Home page
Hace 13 horas